John W Park

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo
    Kevin C Weng
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
    Nano Lett 8:2851-7. 2008
  2. ncbi request reprint Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery
    John W Park
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 8:1172-81. 2002
  3. ncbi request reprint Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
    John W Park
    University of California, San Francisco Cancer Center, San Francisco, California 94115 1710, USA
    Clin Cancer Res 10:3885-96. 2004
  4. ncbi request reprint Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer
    John W Park
    University of California, San Francisco, San Francisco, CA 94115 1710, USA
    J Clin Oncol 25:3680-7. 2007
  5. doi request reprint Unraveling the biologic and clinical complexities of HER2
    John W Park
    Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1710, USA
    Clin Breast Cancer 8:392-401. 2008
  6. pmc Liposome-based drug delivery in breast cancer treatment
    John W Park
    UCSF Comprehensive Cancer Center, San Francisco, California 94115 1710, USA
    Breast Cancer Res 4:95-9. 2002
  7. ncbi request reprint Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo
    Christoph Mamot
    Division of Hematology Oncology, University of California at San Francisco, 94115, USA
    Cancer Res 65:11631-8. 2005
  8. pmc Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts
    Michal T Krauze
    Department of Neurological Surgery, University of California, San Francisco, CA 94103 0555, USA
    Neuro Oncol 9:393-403. 2007
  9. pmc Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model
    Ryuta Saito
    Department of Neurological Surgery, University of California at San Francisco, 1855 Folsom Street, Mission Center Building Room 226, San Francisco, CA 94103, USA
    Neuro Oncol 8:205-14. 2006
  10. pmc Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts
    Yoji Yamashita
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94103, USA
    Neuro Oncol 9:20-8. 2007

Detail Information

Publications58

  1. doi request reprint Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo
    Kevin C Weng
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
    Nano Lett 8:2851-7. 2008
    ..9 h as compared to free QDs with t 1/2 < 10 min. In MCF-7/HER2 xenograft models, localization of QD-ILs at tumor sites was confirmed by in vivo fluorescence imaging...
  2. ncbi request reprint Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery
    John W Park
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 8:1172-81. 2002
    ..We previously showed that anti-HER2 immunoliposomes bind efficiently to and internalize in HER2-overexpressing cells in vitro, resulting in intracellular drug delivery...
  3. ncbi request reprint Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
    John W Park
    University of California, San Francisco Cancer Center, San Francisco, California 94115 1710, USA
    Clin Cancer Res 10:3885-96. 2004
  4. ncbi request reprint Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer
    John W Park
    University of California, San Francisco, San Francisco, CA 94115 1710, USA
    J Clin Oncol 25:3680-7. 2007
    ..We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer...
  5. doi request reprint Unraveling the biologic and clinical complexities of HER2
    John W Park
    Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1710, USA
    Clin Breast Cancer 8:392-401. 2008
    ..Other HER2-targeting strategies are also under active investigation...
  6. pmc Liposome-based drug delivery in breast cancer treatment
    John W Park
    UCSF Comprehensive Cancer Center, San Francisco, California 94115 1710, USA
    Breast Cancer Res 4:95-9. 2002
    ....
  7. ncbi request reprint Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo
    Christoph Mamot
    Division of Hematology Oncology, University of California at San Francisco, 94115, USA
    Cancer Res 65:11631-8. 2005
    ..001-0.003). We conclude that anti-EGFR immunoliposomes provide efficient and targeted drug delivery of anticancer compounds and may represent a useful new treatment approach for tumors that overexpress the EGFR...
  8. pmc Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts
    Michal T Krauze
    Department of Neurological Surgery, University of California, San Francisco, CA 94103 0555, USA
    Neuro Oncol 9:393-403. 2007
    ..These findings have implications for further clinical applications of CED-based treatment of brain tumors...
  9. pmc Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model
    Ryuta Saito
    Department of Neurological Surgery, University of California at San Francisco, 1855 Folsom Street, Mission Center Building Room 226, San Francisco, CA 94103, USA
    Neuro Oncol 8:205-14. 2006
    ..0005 versus control). We conclude that the combination of a novel nanoparticle Ls-TPT and CED administration was very effective in treating experimental brain tumors...
  10. pmc Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts
    Yoji Yamashita
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94103, USA
    Neuro Oncol 9:20-8. 2007
    ..We conclude that CED of two liposomal chemotherapeutics (nLs-TPT and PLD) may be an effective treatment option for malignant gliomas...
  11. ncbi request reprint AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging
    Lisa J Wilmes
    Department of Radiology, University of California San Francisco, San Francisco, CA 94143 1290, USA
    Magn Reson Imaging 25:319-27. 2007
    ..Furthermore, the correlative relationship between microvasculature changes and tumor growth inhibition supports DCE-MRI methods as a biomarker of VEGF receptor target inhibition with potential clinical utility...
  12. ncbi request reprint Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain
    Ryuta Saito
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
    Exp Neurol 196:381-9. 2005
    ..Our ability to directly monitor and to control local delivery of liposomal drugs will most likely result in greater clinical efficacy when using CED in management of patients...
  13. ncbi request reprint Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy
    Charles O Noble
    Division of Hematology Oncology, University of California at San Francisco, California 94115, USA
    Cancer Res 66:2801-6. 2006
    ..5 days; P = 0.011). We conclude that CED of nanoliposomal CPT-11 greatly prolonged tissue residence while also substantially reducing toxicity, resulting in a highly effective treatment strategy in preclinical brain tumor models...
  14. ncbi request reprint Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
    ..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery...
  15. ncbi request reprint Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models
    Kevin C Weng
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Nanomedicine (Lond) 8:1913-25. 2013
    ..The aim of this work is to evaluate combining targeting strategy and convection-enhanced delivery in brain tumor models by imaging quantum dot-immunoliposome hybrid nanoparticles...
  16. pmc Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents
    Michal T Krauze
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California 94103, USA
    J Neurosurg 103:923-9. 2005
    ..This step-design cannula may allow reflux-free distribution and shorten the duration of infusion in future clinical applications of CED in humans...
  17. ncbi request reprint Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery
    Christoph Mamot
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA, USA
    J Neurooncol 68:1-9. 2004
    ..To our knowledge, this is the first report of CED infusion of liposomes into the CNS. We conclude that CED of liposomes in the CNS is a feasible approach, and offers a promising strategy for targeting therapeutic agents to brain tumors...
  18. pmc Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts
    Laura P Serwer
    Department of Neurological Surgery, University of California San Francisco, 1450 Third St, San Francisco, CA 94158, USA
    Neuro Oncol 13:1288-95. 2011
    ..These results demonstrate that intravenous delivery of nLS-TPT is a promising strategy in the treatment of GBM and support clinical investigation of this therapeutic approach...
  19. ncbi request reprint Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells
    Christoph Mamot
    Division of Hematology Oncology, University of California, San Francisco, 94115, USA
    Cancer Res 63:3154-61. 2003
    ..We conclude that EGFR-targeted ILs provide efficient and targeted delivery of anticancer drugs in cells overexpressing EGFR or EGFRvIII...
  20. ncbi request reprint Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis
    Ulrik B Nielsen
    Department of Anesthesia and Pharmaceutical Chemistry, University of California San Francisco, SF General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Biochim Biophys Acta 1591:109-118. 2002
    ..This strategy should be applicable to generate immunotherapeutics for other malignancies by selecting phage antibodies for internalization into other tumor types and using the scFv to target liposomes or other nanoparticles...
  21. pmc Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients
    Mark Jesus M Magbanua
    Division of Hematology Oncology, University of California San Francisco, San Francisco, CA 94115, USA
    Cancer Res 73:30-40. 2013
    ..Our approach may be used to explore genomic events involved in cancer progression and to monitor therapeutic efficacy of targeted therapies in clinical trials in a relatively noninvasive manner...
  22. doi request reprint Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation
    Peter J Dickinson
    Department of Surgical and Radiological Sciences, Tupper Hall, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
    J Neurosurg 108:989-98. 2008
    ..Additionally any possible toxicity of liposomes containing Gd and the chemotherapeutic agent irinotecan (CPT-11) was assessed following direct intraparenchymal delivery...
  23. ncbi request reprint Real-time imaging and quantification of brain delivery of liposomes
    Michal T Krauze
    Department of Neurological Surgery, Laboratory for Molecular Therapeutics, University of California San Francisco, San Francisco, California, USA
    Pharm Res 23:2493-504. 2006
    ..This review is a summary of work done by our group over the past four years...
  24. ncbi request reprint Future directions of liposome- and immunoliposome-based cancer therapeutics
    John W Park
    UCSF Comprehensive Cancer Center, San Francisco, CA 94115 1710, USA
    Semin Oncol 31:196-205. 2004
    ....
  25. pmc The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain
    Piotr Hadaczek
    Laboratory of Molecular Therapeutics, Department of Neurological Surgery, UCSF, MCB, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
    Mol Ther 14:69-78. 2006
    ....
  26. ncbi request reprint Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging
    Ryuta Saito
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, California 94103, USA
    Cancer Res 64:2572-9. 2004
    ..By permitting in vivo monitoring of therapeutic distribution in brain tumors, this technique optimizes local drug delivery and may provide a basis for clinical applications in the treatment of malignant glioma...
  27. ncbi request reprint Liposome-based approaches to overcome anticancer drug resistance
    Christoph Mamot
    Division of Hematology Oncology, University of California, San Francisco UCSF, 2340 Sutter Street, San Francisco, CA 94115, USA
    Drug Resist Updat 6:271-9. 2003
    ..These agents selectively deliver drug to tumor cells, can efficiently internalize for intracellular drug release, and can potentially enhance both efficacy and safety...
  28. pmc A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S Rugo
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, B 608, San Francisco, CA 94143, USA
    Breast Cancer Res Treat 134:13-20. 2012
    ..Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents...
  29. ncbi request reprint Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI
    Ka Loh Li
    Department of Radiology, University of California San Francisco, San Francisco, California 94143 1290, USA
    J Magn Reson Imaging 22:511-9. 2005
    ....
  30. ncbi request reprint Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging
    Michal T Krauze
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
    Brain Res Brain Res Protoc 16:20-6. 2005
    ..Findings presented in this manuscript may allow for modeling of parameters used for direct delivery of therapeutics into various regions of the brain...
  31. ncbi request reprint Biologic markers determine both the risk and the timing of recurrence in breast cancer
    Laura J Esserman
    Department of Surgery and Radiology, University of California, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 129:607-16. 2011
    ..Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed...
  32. ncbi request reprint Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer
    Jorge A Garcia
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    BJU Int 99:519-24. 2007
    ....
  33. ncbi request reprint Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling
    Mark Jesus M Magbanua
    Division of Hematology Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, United States
    Methods 64:114-8. 2013
    ..Downstream molecular analyses of single and pooled cells confirmed the isolation of highly pure CTCs with characteristics typical that of malignant cells. ..
  34. pmc Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Mark Jesus M Magbanua
    Department of Medicine, Division of Hematology Oncology, University of California San Francisco, USA
    BMC Cancer 12:78. 2012
    ..However, it is the molecular characterization of CTCs that offers insight into the biology of these tumor cells in the context of personalized treatment...
  35. ncbi request reprint Immune dysfunction and micrometastases in women with breast cancer
    Michael J Campbell
    Department of Surgery, University of California, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 91:163-71. 2005
    ..These dysregulated T cell responses did not correlate with age, stage of disease, or nodal status. However, we did observe a correlation between number of micrometastases in the bone marrow and T cell responsiveness...
  36. ncbi request reprint Brain metastases of breast cancer
    Michelle E Melisko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 5:253-68. 2005
    ..New approaches include chemotherapy combinations, biologic therapies and novel drug-delivery strategies...
  37. ncbi request reprint A role for biomarkers in the screening and diagnosis of breast cancer in younger women
    Laura J Esserman
    University of California, San Francisco, Department of Surgery, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
    Expert Rev Mol Diagn 7:533-44. 2007
    ..The most effective preventive strategies will be those where a marker predicts risk for the disease, as well as the benefit from preventive interventions...
  38. pmc Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors
    Laura A Petrillo
    Department of Medicine, University of California, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 135:913-22. 2012
    ..Xenograft tumors' gene expression faithfully resembles that of their parent tumors, yet also demonstrates a shift toward more aggressive molecular features...
  39. ncbi request reprint Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
    Brian I Rini
    UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
    Cancer 101:90-5. 2004
    ..Given the historically low objective response rate in RCC, time to disease progression (TTP) as an alternative endpoint was employed to evaluate the antitumor activity of UCN-01 in RCC...
  40. ncbi request reprint Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
    Hope S Rugo
    University of California, San Francisco Comprehensive Cancer Center, USA
    J Clin Oncol 23:5474-83. 2005
    ....
  41. pmc A comparison of RNA amplification techniques at sub-nanogram input concentration
    Julie E Lang
    Department of Surgery, UCSF Comprehensive Cancer Center, 1500 Divisadero Street, San Francisco, CA 94143, USA
    BMC Genomics 10:326. 2009
    ..Microarray data from each amplification method were validated against quantitative real-time PCR (QPCR) for 37 genes...
  42. ncbi request reprint Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3881-4. 2004
  43. ncbi request reprint Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery
    Ryuta Saito
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, Mission Center Building, 94103, USA
    J Neurosci Methods 154:225-32. 2006
    ..Thus, an increased and more predictable tissue distribution can be achieved by reducing the tissue affinity of the infusate using appropriately engineered liposomes or other nanoparticles...
  44. ncbi request reprint Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2
    Peter Nagy
    Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, POB 39, Debrecen H 4012, Hungary
    J Cell Sci 115:4251-62. 2002
    ..We conclude that local densities of ErbB2 and ErbB3, as well as the lipid environment profoundly influence the association properties and biological function of ErbB2...
  45. ncbi request reprint Applications of fluorescence resonance energy transfer for mapping biological membranes
    Janos Szollosi
    Department of Biophysics and Cell Biology, Faculty of Medicine, Medical and Health Science Center, University of Debrecen, Hungary
    J Biotechnol 82:251-66. 2002
    ....
  46. ncbi request reprint Development of ligand-targeted liposomes for cancer therapy
    Charles O Noble
    University of California at San Francisco, CA 94143, USA
    Expert Opin Ther Targets 8:335-53. 2004
    ..Anti-HER2 immunoliposomal doxorubicin is awaiting Phase I clinical trials, the results of which should provide new insights into the promise of ligand-targeted liposomal therapies...
  47. ncbi request reprint The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Nicholas J Robert
    The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
    Semin Oncol 31:106-46. 2004
    ..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
  48. ncbi request reprint Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines
    Maria Magdalena Mocanu
    Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, Faculty of Medicine, Medical and Health Science Center, University of Debrecen, P O Box 39, Nagyerdei krt 98, H 4012 Debrecen, Hungary
    Cancer Lett 227:201-12. 2005
    ..Our results imply that the true significance of the expression profile of proteins involved in oncogenesis can only be understood after characterizing their molecular interactions...
  49. ncbi request reprint EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells
    Christoph Mamot
    Division of Oncology, Department of Internal Medicine, University Hospital of Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Drug Target 14:215-23. 2006
    ..We conclude that EGFR-targeted ILs derived from the humanized MAb EMD72000 provide efficient and targeted delivery of anticancer drugs in colorectal cancer cells overexpressing EGFR...
  50. ncbi request reprint Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    J Clin Oncol 23:5464-73. 2005
    ..Here we present the pharmacodynamic response to acute dosing of AG-013736 measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)...
  51. ncbi request reprint Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription
    Corina Marx
    Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
    Assay Drug Dev Technol 4:273-84. 2006
    ....
  52. ncbi request reprint Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:221-32. 2005
    ....
  53. ncbi request reprint Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:205-20. 2005
    ..Residual endotoxin, rProtein A, and genomic DNA, were at acceptable levels. This study successfully addressed a necessary step in the scale-up of immunoliposome-encapsulated therapeutics...
  54. ncbi request reprint Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
    Corina Marx
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
    Mol Pharmacol 71:1525-34. 2007
    ....
  55. ncbi request reprint Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Cancer Res 66:3271-7. 2006
    ..This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity...
  56. ncbi request reprint Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor
    Mark Barok
    Department of Biophysics and Cell Biology, University of Debrecen, 4012 Debrecen, Egyetem ter 1, Hungary
    Cancer Lett 260:198-208. 2008
    ..Thus, trastuzumab treatment might also be beneficial in the case of patients with breast cancer that is already trastuzumab resistant...
  57. ncbi request reprint Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins
    Peter Nagy
    Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
    Cytometry A 67:86-96. 2005
    ..Fusing green fluorescent protein (GFP) to a studied protein usually does not disturb the normal function of a protein, but quantitation of FRET efficiency calculated between GFP derivatives poses a problem in flow cytometry...
  58. ncbi request reprint Selecting the right fluorophores and flow cytometer for fluorescence resonance energy transfer measurements
    Gabor Horvath
    Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
    Cytometry A 65:148-57. 2005
    ..Availability of new fluorophores and cytometers requires the establishment of fluorophore dye pairs most suitable for FCET measurements...